U.S. markets closed

Sanofi (SAN.PA)

Paris - Paris Precio retrasado. Divisa en EUR.
Añadir a la lista de seguimiento
90.60+5.21 (+6.10%)
Al cierre: 05:39PM CET

Sanofi

54, Rue La BoEtie
Paris 75008
France
33 1 53 77 40 00
https://www.sanofi.com

Sector(es)Healthcare
IndustriaDrug Manufacturers—General
Empleados a tiempo completo95,442

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Paul HudsonCEO & Director5.64MN/D1967
Mr. Jean-Baptiste Chasseloup de ChatillonExec. VP & CFON/DN/D1965
Mr. Laurent GilhodesPrincipal Accounting Officer and VP of Corp. AccountingN/DN/DN/D
Mr. Bruno MénardChief Information officerN/DN/DN/D
Dr. Josephine FubaraChief Science Officer of Consumer Health CareN/DN/DN/D
Eva Schaefer-JansenHead of Investor RelationsN/DN/DN/D
Mr. Dante BeccariaGlobal Compliance Officer & VPN/DN/DN/D
Mr. Roy PapatheodorouExec. VP, Gen. Counsel and Head of Legal, Ethics & Bus. IntegrityN/DN/D1978
Mr. Josep CatllaHead of CommunicationsN/DN/DN/D
Mr. Pierre ChancelSr. VP of Global Diabetes and Sr. VP of Global MarketingN/DN/D1957
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Gestión corporativa

La calificación ISS Governance QuickScore de Sanofi a partir del 1 de diciembre de 2022 es 3. Las puntuaciones principales son Auditoría: 3; Junta: 5; Derechos del accionista: 5; Compensación: 2.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.